Replies to post #572 on Gamida Cell Ltd (fka GMDAQ)

[midastouch017]

Verdict
As they say in Latin, 'Iacta alea est' or the die is cast, in relation to Gamida. The company's and stock's future will be determined on how fast it can build sales traction for Omisirge. Fortunately, about 80% of individuals that will receive this therapy will come from approximately 70 transplant centers across the U.S. A relatively small sales force is needed to serve this population. Gamida will be targeting 10 to 15 of these centers within its initial launch of Omisirge. It should be able to rapidly roll this therapy out to additional centers as additional resources become available. Management has stated that from a manufacturing, account management, and market access perspective, they are a full 'go' for launch.

We have initiated partnerships to educate and onboard Transplant Centers
November Company Presentation

I would agree that if no partnerships found, additional cash will be required hence
the market is wary and as a consequence pps remains stagnant.